Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vactosertib + Durvalumab in Advanced NSCLC
NCT03732274Phase 2Completed
- Sponsor
- MedPacto
- Start
- Feb 2019
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vactosertib in non-small cell lung cancer (NSCLC), sponsored by MedPacto. Primary endpoint: Maximum Tolerated Dose at 4 weeks. Started Feb 2019; status: completed.
02
Drugs
vactosertib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03732274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03732274.